SecBot SecBot
SECBOTREPLAY Home › Report › TMCI

TMCI · Q3 revenue -4% YoY to $48.3M

TREACE MEDICAL CONCEPTS, INC. · 8-K filed Nov 6, 2026 at 07:05 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Nov 6, 2026 at 07:05 ET

Treace Medical Concepts reported Q3 2026 revenue of $48.3M, down 4% YoY from $50.2M, but net loss narrowed 23% to $(12.6)M and Adjusted EBITDA turned positive at $0.3M. The company narrowed its full-year 2026 revenue guidance to $206M-$210M (from $204M-$212M) and improved its Adjusted EBITDA loss guidance to $1.0M-$2.0M (from $3.0M-$5.0M). Revenue decline persists due to product mix shift toward lower-priced minimally invasive products, though case volume grew double digits.

  • Q3 2026 revenue $48.3M, down 4% from $50.2M in Q3 2025
  • GAAP net loss $(12.6)M, improved 23% from $(16.3)M in Q3 2025
  • Adjusted EBITDA turned positive to $0.3M from $(2.6)M in Q3 2025
  • Full-year 2026 revenue guidance narrowed to $206M-$210M from $204M-$212M

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access